Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 60

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 60
---
 while Ms. MacDonald 
 was on maternity leave. Ms. MacDonald resumed her role as Chief Financial Officer on August 1, 2024, upon her return from maternity  
 leave.                                                                                                                               |

Kelly MacDonald – Senior Vice President, Chief Financial Officer

Ms. MacDonald joined Dynavax in March 2021 as Senior Vice President,
Chief Financial Officer, and Principal Financial Officer, and Ms. MacDonald was appointed as Principal Accounting Officer in February
2025. Prior to Dynavax, Ms. MacDonald worked at Ironwood Pharmaceuticals, Inc. from 2013 to 2021 where she held roles of increasing responsibility.
In her final role at Ironwood, Ms. MacDonald served as Chief Accounting Officer and Vice President, Finance where she led the Company’s
corporate accounting and finance processes, enterprise risk management, treasury and capital allocation strategy. While at Ironwood, she
also had various other finance and accounting managerial roles where she provided financial advice on the company’s strategic planning,
accounting policies, R&D portfolio management, global business development, product launches and commercial execution. Prior to that,
from 2006 to 2013, Ms. MacDonald worked at PriceWaterhouseCoopers, LLP, ultimately serving as a Manager in the Health Industries Assurance
Practice, primarily serving clients in life sciences and technology sectors. Ms. Macdonald is a CPA (MA, inactive) and holds a Master
of Business Administration from the Isenberg School of Management at the University of Massachusetts and a Bachelor of Science in Accounting
from Fairfield University.

David F. Novack – President and Chief Operating Officer

Mr. Novack joined Dynavax in March 2013 as Senior Vice President, Operations
and Quality, served as an interim co-President between May and December 2019, and has served as our President and Chief Operating Officer
since December 2019. Mr. Novack was formerly with Novartis Vaccines & Diagnostics where he served since 2009 as the Global Head of
Technical Operations for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis,
Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr.
Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations,
and supply chain. Previously, from 1989 to